{"organizations": [], "uuid": "93a3084c9dce1e8f09a119741ebcbb00479f7411", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 5, "shares": 5, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-otsukas-tolvaptan-approved-by-us-f/brief-otsukas-tolvaptan-approved-by-u-s-fda-as-first-treatment-to-slow-kidney-function-decline-in-adults-at-risk-of-rapidly-progressing-adpkd-idUSL3N1S21KP", "country": "US", "domain_rank": 408, "title": "BRIEF-Otsuka's tolvaptan approved by U.S. FDA as first treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.714, "site_type": "news", "published": "2018-04-25T10:48:00.000+03:00", "replies_count": 0, "uuid": "93a3084c9dce1e8f09a119741ebcbb00479f7411"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-otsukas-tolvaptan-approved-by-us-f/brief-otsukas-tolvaptan-approved-by-u-s-fda-as-first-treatment-to-slow-kidney-function-decline-in-adults-at-risk-of-rapidly-progressing-adpkd-idUSL3N1S21KP", "ord_in_thread": 0, "title": "BRIEF-Otsuka's tolvaptan approved by U.S. FDA as first treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD", "locations": [], "entities": {"persons": [{"name": "otsuka", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "otsuka pharmaceutical co., ltd.", "sentiment": "neutral"}, {"name": "reuters) - otsuka holdings co ltd", "sentiment": "neutral"}, {"name": "u.s. fda", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Otsuka Holdings Co Ltd\n* Says its unit Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JYNARQUEâ„¢ (tolvaptan) as the first drug treatment available to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)\nSource text in Japanese: goo.gl/7tfVkk\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://twitter.com/reuters", "https://goo.gl/7tfVkk", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T10:48:00.000+03:00", "crawled": "2018-04-25T14:35:49.008+03:00", "highlightTitle": ""}